BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20919855)

  • 1. Long-term survival following allogeneic or syngeneic stem cell transplant for follicular lymphoma in Sweden.
    Lazarevic VL; Hägglund H; Remberger M; Wahlin A; Hallböök H; Juliusson G; Kimby E; Malm C; Omar H; Johansson JE
    Leuk Lymphoma; 2011 Jan; 52(1):69-71. PubMed ID: 20919855
    [No Abstract]   [Full Text] [Related]  

  • 2. Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project.
    Evens AM; Vanderplas A; LaCasce AS; Crosby AL; Nademanee AP; Kaminski MS; Abel GA; Millenson M; Czuczman MS; Rodriguez MA; Niland J; Zelenetz AD; Gordon LI; Friedberg JW
    Cancer; 2013 Oct; 119(20):3662-71. PubMed ID: 23921646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follicular Lymphoma: Redefining Prognosis, Current Treatment Options, and Unmet Needs.
    Welaya K; Casulo C
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):627-638. PubMed ID: 31229159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.
    Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B
    J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.
    Lunning MA; Migliacci JC; Hilden P; Devlin SM; Castro-Malaspina H; Giralt S; Perales MA; Zelenetz AD; Moskowitz CH; Sauter CS
    Br J Haematol; 2016 Apr; 173(2):260-4. PubMed ID: 26847389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.
    Bourcier J; Gastinne T; Leux C; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Voldoire M; Guillaume T; Peterlin P; Gallas P; Garnier A; Maisonneuve H; Moreau P; Juge-Morineau N; Jardel H; Chevallier P; Moreau P; Le Gouill S
    Ann Hematol; 2016 Aug; 95(8):1287-93. PubMed ID: 27297970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma.
    Andresen S; Brandt J; Dietrich S; Memmer ML; Ho AD; Witzens-Harig M
    Leuk Lymphoma; 2012 Mar; 53(3):386-93. PubMed ID: 21864036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin.
    Stein RS; Greer JP; Goodman S; Kallianpur A; Ahmed MS; Wolff SN
    Bone Marrow Transplant; 1999 Feb; 23(3):227-33. PubMed ID: 10084253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
    Krishnan A; Nademanee A; Fung HC; Raubitschek AA; Molina A; Yamauchi D; Rodriguez R; Spielberger RT; Falk P; Palmer JM; Forman SJ
    J Clin Oncol; 2008 Jan; 26(1):90-5. PubMed ID: 18025438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of follicular non-Hodgkin's lymphoma: the old and the new.
    Friedberg JW
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S2-6. PubMed ID: 18760706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
    Kuruvilla J; Pond G; Tsang R; Gupta V; Lipton JH; Messner HA
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):775-82. PubMed ID: 18541196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.
    Andreadis C; Schuster SJ; Chong EA; Svoboda J; Luger SM; Porter DL; Tsai DE; Nasta SD; Elstrom RL; Goldstein SC; Downs LH; Mangan PA; Cunningham KA; Hummel KA; Gimotty PA; Siegel DL; Glatstein E; Stadtmauer EA
    Bone Marrow Transplant; 2005 Dec; 36(11):955-61. PubMed ID: 16205727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of follicularity on autologous transplantation for large-cell non-Hodgkin's lymphoma.
    Vose JM; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Chan WC; Greiner TC; Armitage JO
    J Clin Oncol; 1998 Mar; 16(3):844-9. PubMed ID: 9508164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.
    Brown JR; Feng Y; Gribben JG; Neuberg D; Fisher DC; Mauch P; Nadler LM; Freedman AS
    Biol Blood Marrow Transplant; 2007 Sep; 13(9):1057-65. PubMed ID: 17697968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment.
    Sancho JM; García O; Mercadal S; Pomares H; Fernández-Alvarez R; González-Barca E; Tapia G; González-García E; Moreno M; Domingo-Domènech E; Sorigué M; Navarro JT; Motlló C; Fernández-de-Sevilla A; Feliu E; Ribera JM
    Leuk Res; 2015 Aug; 39(8):853-8. PubMed ID: 26122511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score.
    Peters AC; Duan Q; Russell JA; Duggan P; Owen C; Stewart DA
    Leuk Lymphoma; 2011 Nov; 52(11):2124-9. PubMed ID: 21740097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
    Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report.
    Marangon M; Pellegrini C; Argnani L; Zinzani PL
    Tumori; 2017 Nov; 103(Suppl. 1):e41-e43. PubMed ID: 28967090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive treatment in follicular non-Hodgkin's lymphoma.
    Schouten HC
    Br J Hosp Med; 1996 Nov 20-Dec 10; 56(10):525-8. PubMed ID: 8958406
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.